|1.||Skolnick, Phil: 3 articles (11/2012 - 01/2008)|
|2.||Beer, Bernard: 1 article (04/2010)|
|3.||Czobor, Pál: 1 article (04/2010)|
|4.||Lippa, Arnold: 1 article (04/2010)|
|5.||Gravielle, Maria C: 1 article (01/2008)|
|6.||Farb, David H: 1 article (01/2008)|
|7.||Downing, Scott: 1 article (01/2008)|
|8.||Kostakis, Emmanuel: 1 article (01/2008)|
|9.||Gibbs, Terrell T: 1 article (01/2008)|
|10.||Basile, Anthony S: 1 article (01/2008)|
|1.||Anxiety Disorders (Anxiety Disorder)
04/01/2010 - "A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder."
05/17/2005 - "These findings indicate that ocinaplon represents a unique approach both for the treatment and understanding of anxiety disorders."
01/01/2008 - "The pyrazolo[1,5-a]-pyrimidine ocinaplon is anxioselective in both preclinical studies and in patients with generalized anxiety disorder, but does not exhibit the selectivity between alpha1/alpha2-containing receptors for an anxioselective that is predicted by studies using transgenic mice. "
05/17/2005 - "Here we report that the pyrazolo[1,5-a]-pyrimidine, ocinaplon, exhibits an anxioselective profile in both preclinical procedures and in patients with generalized anxiety disorder, the most common of the anxiety disorders. "
05/01/2005 - "The status of these and other BZ site compounds with claimed, but often not explicitly stated, GABA(A) subtype selectivity (such as ELB-139 and ocinaplon) will be reviewed in relation to their development as non-sedating anxiolytics for the treatment of generalised anxiety disorder."
05/17/2005 - "In this study, the incidence of benzodiazepine-like side effects (e.g., sedation, dizziness) in ocinaplon-treated patients did not differ from placebo. "
11/01/2012 - "In contrast to the anxioselective profile displayed in preclinical models, compounds such as bretazenil, TPA023, and MRK 409 produced benzodiazepine-like side effects (sedation, dizziness) in Phase I studies, whereas alpidem and ocinaplon exhibited many of the characteristics of an anxioselective in the clinic. "
|3.||7- (1,1- dimethylethyl)- 6- (2- ethyl- 2H- 1,2,4- triazol- 3- ylmethoxy)- 3- (2- fluorophenyl)- 1,2,4- triazolo(4,3- b)pyridazine
|6.||Anti-Anxiety Agents (Anxiolytics)
|7.||gamma-Aminobutyric Acid (GABA)
|8.||1- (4- chlorophenyl)- 4- piperidin- 1- yl- 1,5- dihydroimidazol- 2- one